Market Cap 160.36B
Revenue (ttm) 29.44B
Net Income (ttm) 8.51B
EPS (ttm) N/A
PE Ratio 15.43
Forward PE N/A
Profit Margin 28.90%
Debt to Equity Ratio 0.95
Volume 15,369,301
Avg Vol 6,374,704
Day's Range N/A - N/A
Shares Out 1.24B
Stochastic %K 21%
Beta 0.31
Analysts Strong Sell
Price Target $159.20

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 574 3000
Fax: 650 522 5853
Address:
333 Lakeside Drive, Foster City, United States
SilverEagle
SilverEagle Jun. 5 at 3:35 PM
$GILD 155 tagged. Retested its base. Round 2 to 198
0 · Reply
WallStJesus
WallStJesus Jun. 5 at 3:28 PM
$GILD BULL BET..
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 2:18 PM
$GILD Share Price: $129.77 Contract Selected: Jun 26, 2026 $130 Calls Buy Zone: $2.21 – $2.73 Target Zone: $4.03 – $4.92 Potential Upside: 72% ROI Time to Expiration: 20 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
PickAlpha
PickAlpha Jun. 5 at 11:58 AM
4/8: Gilead and Lakefront close Ouro Medicines acquisition; GILD pays $1.675B upfront plus up to $500M milestones to add OM336 (gamgertamig) to inflammation pipeline; Lakefront earns 20%–23% royalties. $GILD $LKFT $XBI $IBB
0 · Reply
thefourpercent
thefourpercent Jun. 5 at 10:39 AM
$GILD going to buy here
0 · Reply
truehealthvalue
truehealthvalue Jun. 5 at 9:37 AM
$GILD I would look at $ELTX, About to take off, it will be worth billions in a short time
0 · Reply
focafoca99
focafoca99 Jun. 4 at 8:45 PM
$GILD announced the completion of its acquisition of Ouro Medicines, adding the gamgertamig T‑cell engager to its inflammation pipeline. https://www.rapidticker.com/news/gild-gilead-sciences-and-lakefront-complete-a70f9d
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 4 at 6:42 PM
$SLS Just the Secondary Asset is Right Now Already worth $24 PER SHARE. A tasty little $4.9B Amuse-Bouche - SLS009 Phase2B Expansion, Randomized - Pivotal Trial Enrollment, Paid for by the EU will be Announced Shortly. SLS009 Phase 2B Enrollment PR expected Friday or Monday "Estimated recruitment start date in EU/EEA: 01/06/2026" euclinicaltrials.eu/ctis-pu... AML-MR / the Highest Risk of AML, most dire Prognosis and 009 Phase 2B AML-MR Data Previously Published at ASH is better, than Magrolimab P1B AML-MR Data Published at ASH that $GILD Paid $4.9B for ...
0 · Reply
skcots_13
skcots_13 Jun. 4 at 5:48 PM
$GILD $150 would represent roughly +16% upside from here. That's within the range of analyst expectations. Gilead has a solid HIV franchise (Biktarvy remains a powerhouse with long exclusivity), growing liver portfolio (positive Livdelzi data recently, Hepcludex approval), and oncology assets like Trodelvy + CAR-T/Yescarta. Recent acquisitions (e.g., Tubulis) and pipeline momentum in PrEP (lenacapavir/Yeztugo) support growth. Let's say, within the next 6–12 months that looks realistic if the pipeline executes and the market cooperates, many of these wh@re analysts already price in more than that.
0 · Reply
ShinnosukeNohara
ShinnosukeNohara Jun. 4 at 2:58 PM
$ASMB totally undervalued. $XBI $GILD
0 · Reply
Latest News on GILD
Gilead announces launch of lenacapavir in South Africa

2026-06-05T09:10:34.000Z - 2 days ago

Gilead announces launch of lenacapavir in South Africa


Gilead announces results from Phase 3 study of Livdelzi

2026-06-02T12:38:50.000Z - 4 days ago

Gilead announces results from Phase 3 study of Livdelzi


Gilead presents new Livdelzi data at EASL congress

2026-05-27T09:25:10.000Z - 11 days ago

Gilead presents new Livdelzi data at EASL congress


US FDA approves Gilead's drug for deadly liver infection

May 22, 2026, 2:06 PM EDT - 15 days ago

US FDA approves Gilead's drug for deadly liver infection


Gilead receives positive CHMP opinion for Trodelvy in TNBC

2026-05-22T12:17:36.000Z - 15 days ago

Gilead receives positive CHMP opinion for Trodelvy in TNBC


Gilead completes acquisition of Tubulis for $3.15B upfront

2026-05-21T13:36:40.000Z - 16 days ago

Gilead completes acquisition of Tubulis for $3.15B upfront


Gilead upgraded to Buy from Hold at Maxim

2026-05-20T12:16:14.000Z - 17 days ago

Gilead upgraded to Buy from Hold at Maxim


Gilead Prices $3 Billion of Senior Unsecured Notes

May 14, 2026, 9:21 PM EDT - 23 days ago

Gilead Prices $3 Billion of Senior Unsecured Notes


Gilead price target raised to $157 from $155 at Truist

2026-05-08T15:05:33.000Z - 4 weeks ago

Gilead price target raised to $157 from $155 at Truist


Gilead Sciences Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Gilead Sciences Earnings Call Transcript: Q1 2026


Gilead Sciences Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Gilead Sciences Slides: Q1 2026


Gilead Sciences Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Gilead Sciences Earnings release: Q1 2026


Gilead Sciences Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 weeks ago

Gilead Sciences Quarterly report: Q1 2026


Gilead Sciences Announces First Quarter Financial Results

May 7, 2026, 4:01 PM EDT - 4 weeks ago

Gilead Sciences Announces First Quarter Financial Results


Gilead Sciences Slides: Investor presentation

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Gilead Sciences Slides: Investor presentation


Can You Sue A Drug Company For Not Inventing Faster?

May 4, 2026, 5:15 AM EDT - 4 weeks ago

Can You Sue A Drug Company For Not Inventing Faster?


Gilead Sciences Transcript: AGM 2026

Apr 30, 2026, 1:00 PM EDT - 5 weeks ago

Gilead Sciences Transcript: AGM 2026


Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing

Apr 13, 2026, 9:57 PM EDT - 7 weeks ago

Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing


AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Apr 10, 2026, 1:01 PM EDT - 2 months ago

AHF Slams Gilead for Role in Florida AIDS Drug Crisis


Gilead Sciences Transcript: M&A announcement

Apr 7, 2026, 4:30 PM EDT - 2 months ago

Gilead Sciences Transcript: M&A announcement


Gilead Sciences Press release: M&A announcement

Apr 7, 2026, 4:30 PM EDT - 2 months ago

Gilead Sciences Press release: M&A announcement


Gilead Sciences Slides: M&A announcement

Apr 7, 2026, 4:30 PM EDT - 2 months ago

Gilead Sciences Slides: M&A announcement


Gilead to acquire Tubulis GmbH for up to $5 billion

Apr 7, 2026, 8:23 AM EDT - 2 months ago

Gilead to acquire Tubulis GmbH for up to $5 billion


Gilead Extends Tender Offer to Acquire Arcellx

Apr 1, 2026, 4:13 PM EDT - 2 months ago

Gilead Extends Tender Offer to Acquire Arcellx


Markets Haven't Changed. These 2 Cheap Dividends Still Rule

Apr 1, 2026, 10:50 AM EDT - 2 months ago

Markets Haven't Changed. These 2 Cheap Dividends Still Rule

WM


Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

Mar 23, 2026, 6:55 PM EDT - 2 months ago

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion


Gilead Sciences Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 2 months ago

Gilead Sciences Proxy statement: Proxy filing


Gilead Sciences Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 2 months ago

Gilead Sciences Proxy statement: Proxy filing


5 Stocks to Buy in a High-Risk Bull Market

Mar 19, 2026, 2:15 PM EDT - 2 months ago

5 Stocks to Buy in a High-Risk Bull Market

AAPL C JCI PYPL


Johanna Mercier on Gilead's HIV prevention innovation

Feb 27, 2026, 2:30 PM EST - 3 months ago

Johanna Mercier on Gilead's HIV prevention innovation


SilverEagle
SilverEagle Jun. 5 at 3:35 PM
$GILD 155 tagged. Retested its base. Round 2 to 198
0 · Reply
WallStJesus
WallStJesus Jun. 5 at 3:28 PM
$GILD BULL BET..
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 2:18 PM
$GILD Share Price: $129.77 Contract Selected: Jun 26, 2026 $130 Calls Buy Zone: $2.21 – $2.73 Target Zone: $4.03 – $4.92 Potential Upside: 72% ROI Time to Expiration: 20 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
PickAlpha
PickAlpha Jun. 5 at 11:58 AM
4/8: Gilead and Lakefront close Ouro Medicines acquisition; GILD pays $1.675B upfront plus up to $500M milestones to add OM336 (gamgertamig) to inflammation pipeline; Lakefront earns 20%–23% royalties. $GILD $LKFT $XBI $IBB
0 · Reply
thefourpercent
thefourpercent Jun. 5 at 10:39 AM
$GILD going to buy here
0 · Reply
truehealthvalue
truehealthvalue Jun. 5 at 9:37 AM
$GILD I would look at $ELTX, About to take off, it will be worth billions in a short time
0 · Reply
focafoca99
focafoca99 Jun. 4 at 8:45 PM
$GILD announced the completion of its acquisition of Ouro Medicines, adding the gamgertamig T‑cell engager to its inflammation pipeline. https://www.rapidticker.com/news/gild-gilead-sciences-and-lakefront-complete-a70f9d
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 4 at 6:42 PM
$SLS Just the Secondary Asset is Right Now Already worth $24 PER SHARE. A tasty little $4.9B Amuse-Bouche - SLS009 Phase2B Expansion, Randomized - Pivotal Trial Enrollment, Paid for by the EU will be Announced Shortly. SLS009 Phase 2B Enrollment PR expected Friday or Monday "Estimated recruitment start date in EU/EEA: 01/06/2026" euclinicaltrials.eu/ctis-pu... AML-MR / the Highest Risk of AML, most dire Prognosis and 009 Phase 2B AML-MR Data Previously Published at ASH is better, than Magrolimab P1B AML-MR Data Published at ASH that $GILD Paid $4.9B for ...
0 · Reply
skcots_13
skcots_13 Jun. 4 at 5:48 PM
$GILD $150 would represent roughly +16% upside from here. That's within the range of analyst expectations. Gilead has a solid HIV franchise (Biktarvy remains a powerhouse with long exclusivity), growing liver portfolio (positive Livdelzi data recently, Hepcludex approval), and oncology assets like Trodelvy + CAR-T/Yescarta. Recent acquisitions (e.g., Tubulis) and pipeline momentum in PrEP (lenacapavir/Yeztugo) support growth. Let's say, within the next 6–12 months that looks realistic if the pipeline executes and the market cooperates, many of these wh@re analysts already price in more than that.
0 · Reply
ShinnosukeNohara
ShinnosukeNohara Jun. 4 at 2:58 PM
$ASMB totally undervalued. $XBI $GILD
0 · Reply
Prady
Prady Jun. 3 at 10:31 PM
$GILD 150 soon.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 3 at 6:34 PM
$SLS Estimated end of trial date in EU/EEA: 01/06/2029 https://euclinicaltrials.eu/ctis-public/view/2025-524308-31-00 SLS009 Phase 2B Enrollment PR expected Friday or Monday 009 Phase 2B AML-MR Data Previously Published at ASH is better, than Magrolimab P1B AML-MR Data Published at ASH that $GILD Paid $4.9B for ... Just the Secondary Asset is Right Now Already worth $24 PER SHARE.
0 · Reply
skcots_13
skcots_13 Jun. 3 at 6:01 PM
$GILD if you owned this for over 5 years it's hard to say no. i'll just continue to say yes.
0 · Reply
whoisjohnwalls
whoisjohnwalls Jun. 3 at 6:12 AM
$GILD $GILD bullish 1–5 yr risk-managed setup. Ref price ~$127.57. Not chasing shares here. Structure: 1 cheap upside spread + lower share ladder. Option kicker: Jun 2027 $150/$170 call spread @ $2.95 debit Max risk: $295 Max value: $2,000 Max profit: $1,705 Breakeven: $152.95 Share ladder: 8 @ $122.25 10 @ $119.25 10 @ $116.25 5 @ $111.25 only if thesis intact Avg cost if full fill: ~$117.86 Total deployed: ~$4,184 Cash reserve: ~$816 Risk/reward from full fill: Risk to $105 failure zone: ~-$719 Reward to $157: ~$1,697 = 2.36:1 R/R Reward to $165: ~$2,761 = 3.84:1 R/R Reward to $170+: ~$3,426 = 4.76:1 R/R 1-yr probability model: 15% bear $108 = -$620 20% chop $124 = -$92 30% base $140 = +$436 20% rebound $147 = +$667 10% retest $157 = +$1,697 5% breakout $165 = +$2,761 1-yr EV: ~$461 pre-divs, ~$569 incl. estimated divs if all shares fill. Big support at $110.
0 · Reply
AXLFI_HQ
AXLFI_HQ Jun. 2 at 2:25 PM
$GILD Specialty pharmaceutical and biotech companies are pursuing strategic acquisitions, portfolio optimization, and regulatory approvals to unlock shareholder value and consolidate market position amid capital efficiency pressures. Learn more: https://axlfi.com/themes/309
0 · Reply
focafoca99
focafoca99 Jun. 2 at 1:06 PM
$GILD demonstrates strong Phase 3 results with Livdelzi achieving ALP normalization in PBC. https://www.rapidticker.com/news/gild-gileads-livdelzi-seladelpar-delivers-statistically-c687
0 · Reply
ShinnosukeNohara
ShinnosukeNohara Jun. 1 at 3:43 PM
$ASMB $GILD #shorties 100% Team Asmb
0 · Reply
harmongreg
harmongreg May. 31 at 4:31 PM
Dragonfly Capital - 5 Trade Ideas for Monday: Affirm, Dexcom, Gilead, Old Dominion and UPS $AFRM $DXXCM $GILD $ODFL $UPS https://dragonflycap.com/5-trade-ideas-for-monday-affirm-dexcom-gilead-old-dominion-and-ups/ + Holiday Discount Pricing 30% off
0 · Reply
None_
None_ May. 31 at 4:05 AM
$GILD https://www.apexonco.com/asco-2026-tubulis-flaunts-what-it-was-bought
0 · Reply
None_
None_ May. 31 at 1:17 AM
$GILD https://x.com/JacobPlieth/status/2060717804119077183
0 · Reply
cubie
cubie May. 29 at 8:17 PM
$MRK $BMY $JNJ $REPL $GILD interesting and see cubie had $REPL a week ago. ur welcome if u made whopping 14,000% there today. wowee
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 29 at 5:05 PM
$SLS $GILD The share Price will Continue Climbing until we Get the 80th EVENT PR and then its Absolute Moon Launch Mode --- watch. The first ever, safe effective Immunotherapy for AML Remission Maintenance, with a compounded Dosing Regime --- is worth Many Tens of billions to Big Pharma.
0 · Reply